ALIESHA GRIFFIN ET AL: "Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome", BRAIN, 10 January 2017 (2017-01-10), page aww342, XP055704572, ISSN: 0006-8950, DOI: 10.1093/brain/aww342 (B1)

WO-A2-2009/105507 (B1)

Anonymous: "Lennox-Gastaut Syndrome", Rare diseases, 1 January 2019 (2019-01-01), pages 1-15, XP055704569, Retrieved from the Internet: URL:https://rarediseases.org/rare-diseases /lennox-gastaut-syndrome/ [retrieved on 2020-06-12] (B1)

DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; November 1994 (1994-11), DEVINSKY O ET AL: "Epilepsy and sleep apnea syndrome.", XP002783989, Database accession no. NLM7969960 & DEVINSKY O ET AL: "Epilepsy and sleep apnea syndrome.", NEUROLOGY NOV 1994, vol. 44, no. 11, November 1994 (1994-11), pages 2060-2064, ISSN: 0028-3878 (B1)

DATABASE WPI Week 201549 Thomson Scientific, London, GB; AN 2015-38134E XP002783990, & WO 2015/096119 A1 (HANGZHOU PUSHAI PHARM TECHNOLOGY CO LTD) 2 July 2015 (2015-07-02) (B1)

EP-A1- 1 787 679 (B1)

GERGELY ORBAN ET AL: "Role(s) of the 5-HT2C Receptor in the Development of Maximal Dentate Activation in the Hippocampus of Anesthetized Rats", CNS NEUROSCIENCE & THERAPEUTICS, vol. 20, no. 7, 17 June 2014 (2014-06-17), pages 651-661, XP055500897, GB ISSN: 1755-5930, DOI: 10.1111/cns.12285 (B1)

GOKUL C G ET AL: "A study on effect of Trazadone, Amoxapine and venlafaxine on MES (maximal electroshock) induced seizures in albino rats", PHARMACOLOGYONLINE, UNIVERSITÀ DEGLI STUDI DI SALERNO, IT , vol. 3 1 January 2011 (2011-01-01), pages 214-221, XP009507525, ISSN: 1827-8620 Retrieved from the Internet: URL:http://www.unisa.it/uploads/5711/22.go kul.pdf (B1)

Guy A. Higgins ET AL: "From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists", Trends in Pharmacological Sciences, vol. 34, no. 10, 1 October 2013 (2013-10-01), pages 560-570, XP055162077, ISSN: 0165-6147, DOI: 10.1016/j.tips.2013.08.001 (B1)

H. Berlie ET AL: "Evaluation of lorcaserin for the treatment of obesity", Expert Opinion on Drug Metabolism and Toxicology, 1 January 2013 (2013-01-01), pages 1053-1059, XP055745734, Retrieved from the Internet: URL:https://www.tandfonline.com/doi/full/1 0.1517/17425255.2013.798643 [retrieved on 2020-10-30] (B1)

Highlights of prescribing information BELVIQ (B1)

ISAAC M: "Serotonergic 5-HT2C receptors as a potential therapeutic target for the design antiepileptic drugs", CURRENT TOPICS IN MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS LTD.HILVERSUM, NL, vol. 5, no. 1, 1 January 2005 (2005-01-01) , pages 59-67, XP009507533, ISSN: 1568-0266, DOI: 10.2174/1568026053386980 (B1)

J. M. RICHTER ET AL: "Clemizole Hydrochloride Is a Novel and Potent Inhibitor of Transient Receptor Potential Channel TRPC5", MOLECULAR PHARMACOLOGY, vol. 86, no. 5, 19 August 2014 (2014-08-19), pages 514-521, XP055519879, DOI: 10.1124/mol.114.093229 (B1)

KINGA K. BOROWICZ ET AL: "Trazodone reduces the anticonvulsant action of certain classical antiepileptics in the mouse maximal electroshock model", PHARMACOLOGICAL REPORTS, vol. 64, no. 5, 1 September 2012 (2012-09-01), pages 1135-1145, XP055500694, PL ISSN: 1734-1140, DOI: 10.1016/S1734-1140(12)70910-6 (B1)

LINDA AZEVEDO KAUPPILA ET AL: "Trazodone: A New Antiepileptic Drug for Dravet Syndrome?", INTERNATIONAL JOURNAL OF EPILEPSY, vol. 05, no. 02, 1 October 2018 (2018-10-01), pages 099-103, XP055704575, ISSN: 2213-6320, DOI: 10.1055/s-0039-1677783 (B1)

PATRICIA TOLETE ET AL: "Lorcaserin therapy for severe epilepsy of childhood onset : A case series", NEUROLOGY, vol. 91, no. 18, 26 September 2018 (2018-09-26), pages 837-839, XP055704567, US ISSN: 0028-3878, DOI: 10.1212/WNL.0000000000006432 (B1)

ROBERT S. FISHER ET AL: "ILAE Official Report: A practical clinical definition of epilepsy", EPILEPSIA, vol. 55, no. 4, 1 April 2014 (2014-04-01), pages 475-482, XP055206122, ISSN: 0013-9580, DOI: 10.1111/epi.12550 (B1)

SCOTT C. BARABAN ET AL: "Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment", NATURE COMMUNICATIONS, vol. 4, 3 September 2013 (2013-09-03), XP055244756, DOI: 10.1038/ncomms3410 (B1)

SMITH STEVEN R ET AL: "Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women", OBESITY RESEARCH, NATURE PUBLISHING GROUP, US, vol. 17, no. 3, 1 March 2009 (2009-03-01), pages 494-503, XP009138506, ISSN: 1930-7381 (B1)

THOMSEN WILLIAM J ET AL: "Lorcaserin, a novel selective human 5-Hydroxytryptamine(2C) agonist: In vitro and in vivo pharmacological characterization", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS,, vol. 325, no. 2, 1 May 2008 (2008-05-01), pages 577-587, XP009138374, ISSN: 0022-3565, DOI: 10.1124/JPET.107.133348 [retrieved on 2008-02-05] (B1)

US-A1- 2003 166 581 (B1)

US-A1- 2005 215 589 (B1)

US-A1- 2008 064 671 (B1)

US-A1- 2011 052 536 (B1)

US-A1- 2014 329 893 (B1)

US-B1- 6 780 869 (B1)

WARTER J-M ET AL: "IMMEDIATE EFFECTS OF 14 NON-MAOI ANTIDEPRESSANTS IN RATS WITH SPONTANEOUS PETIT MAL-LIKE SEIZURES", PROGRESS IN NEURO-PSYCHOPHARMACOLOGY AND BIOLOGICAL PSYCHIATRY, vol. 14, no. 2, 1990, pages 261-270, ISSN: 0278-5846 (B1)

WO-A1-2014/123909 (B1)

WO-A1-2015/026849 (B1)

WO-A1-2016/203239 (B1)

WO-A2-2007/093880 (B1)

WO-A2-2008/133884 (B1)

Anonymous ET AL: "Highlights of prescribing information Belviq", , 1 June 2012 (2012-06-01), pages 1-28, XP055745733, Retrieved from the Internet: URL:https://www.accessdata.fda.gov/drugsat fda_docs/label/2012/022529lbl.pdf [retrieved on 2020-10-30] (B1)